公开(公告)号：US20220412981A1

公开(公告)日：2022-12-29

申请号：US17686565

申请日：2022-03-04

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： David FABRIZIO ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Marcin KOWANETZ ,  David SHAMES ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY ,  Wei ZOU

IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  A61P35/04 ,  A61P35/00 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma. The invention provides methods of treating cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), methods of determining whether a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma) to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from cancer (e.g., lung cancer (e.g., NSCLC), bladder cancer (e.g., UC), kidney cancer (e.g., RCC), breast cancer (e.g., TNBC), or melanoma), based on a tissue tumor mutational burden (tTMB) score, which reflects somatic mutation levels of genes in a tumor tissue sample obtained from the patient, alone or in combination with PD-L1 expression levels (e.g., PD-L1 expression levels in tumor or tumor-infiltrating immune cells in a tumor sample (tumor area) obtained from the patient).

公开(公告)号：US20180371099A1

公开(公告)日：2018-12-27

申请号：US16115343

申请日：2018-08-28

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30 ,  G16H20/10

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20220153861A1

公开(公告)日：2022-05-19

申请号：US17590918

申请日：2022-02-02

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20240392378A1

公开(公告)日：2024-11-28

申请号：US18212949

申请日：2023-06-22

Applicant: Foundation Medicine, Inc. ,  Vanderbilt University

Inventor： Garrett Michael FRAMPTON ,  Roman YELENSKY ,  James Xin SUN ,  Douglas Buckner JOHNSON ,  Christine Marie LOVLY ,  Jeffrey Alan SOSMAN ,  David FABRIZIO ,  Philip James STEPHENS ,  Vincent A. MILLER

IPC: C12Q1/6886 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  G06F17/15 ,  G16B20/00 ,  G16H50/20 ,  G16H50/30

Abstract: Methods and compositions for treating cancer such as melanomas are disclosed.

公开(公告)号：US20210043274A1

公开(公告)日：2021-02-11

申请号：US17077967

申请日：2020-10-22

Applicant: Foundation Medicine, Inc.

Inventor： James Xin SUN ,  Roman YELENSKY

IPC: G16B20/00

Abstract: Methods and systems for analyzing genetic variants are disclosed.